Overview Dividends

(ACLX) Arcellx - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03940C1009

Anitocabtagene Autoleucel, ACLX-001, ACLX-002, ACLX-003, ARC-SparX

EPS (Earnings per Share)

EPS (Earnings per Share) of ACLX over the last years for every Quarter: "2020-12": null, "2021-03": null, "2021-06": null, "2021-09": -1.27, "2021-12": -39.85, "2022-03": -1.56, "2022-06": -0.88, "2022-09": -2.12, "2022-12": -0.76, "2023-03": -0.58, "2023-06": -0.5, "2023-09": -0.81, "2023-12": 0.42, "2024-03": -0.14, "2024-06": -0.51, "2024-09": -0.48, "2024-12": -0.87, "2025-03": -1.13, "2025-06": -0.94, "2025-09": -0.99,
EPS Growth (3y CAGR): -23.79%
EPS Trend (3y Corr): -36.9%
Last SUE: -0.06σ
Qual. Beats: 0

Revenue

Revenue of ACLX over the last years for every Quarter: 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 17.912, 2023-06: 14.302, 2023-09: 14.957, 2023-12: 63.148, 2024-03: 39.256, 2024-06: 27.384, 2024-09: 26.03, 2024-12: 15.266, 2025-03: 8.129, 2025-06: 7.554, 2025-09: 4.949,
Revenue Growth (3y CAGR): 69.60%
Revenue Trend (3y Corr): 10.9%
Last SUE: -0.51σ
Qual. Beats: 0
Risk via 10d forecast
Volatility 44.8%
Value at Risk 5%th 70.3%
Relative Tail Risk -4.62%
Reward TTM
Sharpe Ratio 0.21
Alpha -11.14
Character TTM
Hurst Exponent 0.306
Beta 1.046
Beta Downside 0.972
Drawdowns 3y
Max DD 50.44%
Mean DD 20.06%
Median DD 19.91%

Description: ACLX Arcellx November 08, 2025

Arcellx Inc. (NASDAQ: ACLX) is a U.S. biotech focused on developing cell-based immunotherapies for hematologic malignancies and solid tumors. Its lead candidate, anitocabtagene autoleucel (ddCAR), is in a Phase 2 trial for relapsed or refractory multiple myeloma (RRMM) and is co-developed with Kite Pharma. Additional pipelines include ACLX-001 (Phase 1 BCMA-targeted RRMM), ARC-SparX (Phase 1), ACLX-002 (Phase 1 CD123-targeted AML/MDS), and pre-clinical ACLX-003 for AML/MDS, plus early-stage solid-tumor programs.

Key data points to watch: • As of Q3 2024, Arcellx reported cash and equivalents of roughly $140 million, giving it ~12 months of runway at current burn (~$12 million per quarter). • The BCMA market is projected to exceed $10 billion by 2028, with competitors like BMS and J&J already commercialized, making market share capture a critical driver. • Arcellx’s strategic alliance with Kite provides access to Kite’s manufacturing and commercialization infrastructure, potentially lowering capital-intensive rollout costs.

If you want a more granular look at ACLX’s valuation assumptions and scenario analysis, ValueRay’s analyst commentary can be a useful next step.

ACLX Stock Overview

Market Cap in USD 5,203m
Sub-Industry Biotechnology
IPO / Inception 2022-02-04
Return 12m vs S&P 500 -8.19%
Analyst Rating 4.67 of 5

ACLX Dividends

Currently no dividends paid

ACLX Growth Ratios

Metric Value
CAGR 3y 61.27%
CAGR/Max DD Calmar Ratio 1.21
CAGR/Mean DD Pain Ratio 3.06
Current Volume 847.5k
Average Volume 398.8k

Piotroski VR‑10 (Strict, 0-10) 0.5

Net Income (-217.9m TTM) > 0 and > 6% of Revenue (6% = 2.15m TTM)
FCFTA -0.31 (>2.0%) and ΔFCFTA -31.14pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 985.3% (prev 289.0%; Δ 696.3pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.30 (>3.0%) and CFO -198.1m > Net Income -217.9m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 3.99 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (56.6m) change vs 12m ago 5.14% (target <= -2.0% for YES)
Gross Margin -2.25% (prev 97.36%; Δ -99.61pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 5.05% (prev 20.37%; Δ -15.32pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -11.4k (EBITDA TTM -209.5m / Interest Expense TTM 19.0k) >= 6 (WARN >= 3)

Altman Z'' -5.08

(A) 0.54 = (Total Current Assets 472.1m - Total Current Liabilities 118.4m) / Total Assets 655.9m
(B) -1.02 = Retained Earnings (Balance) -667.6m / Total Assets 655.9m
warn (B) unusual magnitude: -1.02 — check mapping/units
(C) -0.30 = EBIT TTM -216.3m / Avg Total Assets 710.4m
(D) -3.10 = Book Value of Equity -666.9m / Total Liabilities 215.1m
Total Rating: -5.08 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 32.35

1. Piotroski 0.50pt
2. FCF Yield -4.20%
3. FCF Margin data missing
4. Debt/Equity 0.12
5. Debt/Ebitda 0.13
6. ROIC - WACC (= -60.54)%
7. RoE -51.13%
8. Rev. Trend 10.91%
9. EPS Trend -36.90%

What is the price of ACLX shares?

As of November 21, 2025, the stock is trading at USD 89.57 with a total of 847,510 shares traded.
Over the past week, the price has changed by +2.46%, over one month by +3.23%, over three months by +25.26% and over the past year by +2.69%.

Is ACLX a buy, sell or hold?

Arcellx has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy ACLX.
  • Strong Buy: 12
  • Buy: 6
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the ACLX price?

Issuer Target Up/Down from current
Wallstreet Target Price 113.1 26.3%
Analysts Target Price 113.1 26.3%
ValueRay Target Price 120.4 34.4%

ACLX Fundamental Data Overview November 18, 2025

Market Cap USD = 5.20b (5.20b USD * 1.0 USD.USD)
P/S = 144.9357
P/B = 11.8066
Beta = 0.313
Revenue TTM = 35.9m USD
EBIT TTM = -216.3m USD
EBITDA TTM = -209.5m USD
Long Term Debt = 51.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 7.47m USD (from shortTermDebt, last quarter)
Debt = 51.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -27.2m USD (from netDebt column, last quarter)
Enterprise Value = 4.79b USD (5.20b + Debt 51.8m - CCE 461.4m)
Interest Coverage Ratio = -11.4k (Ebit TTM -216.3m / Interest Expense TTM 19.0k)
FCF Yield = -4.20% (FCF TTM -201.2m / Enterprise Value 4.79b)
FCF Margin = -560.4% (FCF TTM -201.2m / Revenue TTM 35.9m)
Net Margin = -607.0% (Net Income TTM -217.9m / Revenue TTM 35.9m)
Gross Margin = -2.25% ((Revenue TTM 35.9m - Cost of Revenue TTM 36.7m) / Revenue TTM)
Gross Margin QoQ = -609.0% (prev 78.58%)
Tobins Q-Ratio = 7.31 (Enterprise Value 4.79b / Total Assets 655.9m)
Interest Expense / Debt = 0.04% (Interest Expense 19.0k / Debt 51.8m)
Taxrate = -0.0% (0.0 / -55.8m)
NOPAT = -216.3m (EBIT -216.3m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 3.99 (Total Current Assets 472.1m / Total Current Liabilities 118.4m)
Debt / Equity = 0.12 (Debt 51.8m / totalStockholderEquity, last quarter 440.8m)
Debt / EBITDA = 0.13 (negative EBITDA) (Net Debt -27.2m / EBITDA -209.5m)
Debt / FCF = 0.14 (negative FCF - burning cash) (Net Debt -27.2m / FCF TTM -201.2m)
Total Stockholder Equity = 426.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.22% (Net Income -217.9m / Total Assets 655.9m)
RoE = -51.13% (Net Income TTM -217.9m / Total Stockholder Equity 426.2m)
RoCE = -45.26% (EBIT -216.3m / Capital Employed (Equity 426.2m + L.T.Debt 51.8m))
RoIC = -50.77% (negative operating profit) (NOPAT -216.3m / Invested Capital 426.2m)
WACC = 9.77% (E(5.20b)/V(5.25b) * Re(9.87%) + D(51.8m)/V(5.25b) * Rd(0.04%) * (1-Tc(-0.0)))
Discount Rate = 9.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.04%
Fair Price DCF = unknown (Cash Flow -201.2m)
EPS Correlation: -36.90 | EPS CAGR: -23.79% | SUE: -0.06 | # QB: 0
Revenue Correlation: 10.91 | Revenue CAGR: 69.60% | SUE: -0.51 | # QB: 0

Additional Sources for ACLX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle